Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients
AuthorWong, SQ; Fellowes, A; Doig, K; Ellul, J; Bosma, TJ; Irwin, D; Vedururu, R; Tan, AY-C; Weiss, J; Chan, KS; ...
Source TitleBritish Journal of Cancer
PublisherNATURE PUBLISHING GROUP
University of Melbourne Author/sEllul, Jason; Fox, Stephen; Thomas, David; Doig, Kenneth; Dobrovic, Alexander
AffiliationSurgery (Austin & Northern Health)
Sir Peter MacCallum Department of Oncology
Document TypeJournal Article
CitationsWong, S. Q., Fellowes, A., Doig, K., Ellul, J., Bosma, T. J., Irwin, D., Vedururu, R., Tan, A. Y. -C., Weiss, J., Chan, K. S., Lucas, M., Thomas, D. M., Dobrovic, A., Parisot, J. P. & Fox, S. B. (2015). Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients. BRITISH JOURNAL OF CANCER, 112 (8), pp.1411-1420. https://doi.org/10.1038/bjc.2015.80.
Access StatusOpen Access
INTRODUCTION: Recent discoveries in cancer research have revealed a plethora of clinically actionable mutations that provide therapeutic, prognostic and predictive benefit to patients. The feasibility of screening mutations as part of the routine clinical care of patients remains relatively unexplored as the demonstration of massively parallel sequencing (MPS) of tumours in the general population is required to assess its value towards the health-care system. METHODS: Cancer 2015 study is a large-scale, prospective, multisite cohort of newly diagnosed cancer patients from Victoria, Australia with 1094 patients recruited. MPS was performed using the Illumina TruSeq Amplicon Cancer Panel. RESULTS: Overall, 854 patients were successfully sequenced for 48 common cancer genes. Accurate determination of clinically relevant mutations was possible including in less characterised cancer types; however, technical limitations including formalin-induced sequencing artefacts were uncovered. Applying strict filtering criteria, clinically relevant mutations were identified in 63% of patients, with 26% of patients displaying a mutation with therapeutic implications. A subset of patients was validated for canonical mutations using the Agena Bioscience MassARRAY system with 100% concordance. Whereas the prevalence of mutations was consistent with other institutionally based series for some tumour streams (breast carcinoma and colorectal adenocarcinoma), others were different (lung adenocarcinoma and head and neck squamous cell carcinoma), which has significant implications for health economic modelling of particular targeted agents. Actionable mutations in tumours not usually thought to harbour such genetic changes were also identified. CONCLUSIONS: Reliable delivery of a diagnostic assay able to screen for a range of actionable mutations in this cohort was achieved, opening unexpected avenues for investigation and treatment of cancer patients.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References